Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Gap Up on Earnings Beat

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)’s stock price gapped up prior to trading on Tuesday following a better than expected earnings announcement. The stock had previously closed at $214.44, but opened at $225.37. Jazz Pharmaceuticals shares last traded at $232.0350, with a volume of 647,883 shares.

The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.05) by $0.17. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. Jazz Pharmaceuticals’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the company earned $8.13 EPS.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Raised 2026 guidance: Jazz now expects approximately $4.8 billion-$4.9 billion in full-year revenue, above the roughly $4.7 billion analyst consensus. The company cited sustained commercial execution and expects the Ziihera launch to support growth. Jazz Pharmaceuticals 2026 revenue guidance
• Positive Sentiment: Q3 beat expectations: Jazz reported quarterly revenue of $1.24 billion, up 10.4% year over year and ahead of the $1.21 billion consensus. Its adjusted loss of $3.88 per share was narrower than the expected $4.05 loss. Xywav revenue grew 12%, with 425 net patient additions during the quarter. Jazz Pharmaceuticals third-quarter 2026 results
• Positive Sentiment: Analyst optimism: Royal Bank of Canada raised its price target to $305 and retained an “outperform” rating, while Barclays increased its target to $275 and maintained an “overweight” rating. The revisions reinforce expectations for additional upside. Royal Bank of Canada Jazz Pharmaceuticals rating
• Neutral Sentiment: Jazz launched Ziihera in first-line HER2-positive metastatic gastroesophageal adenocarcinoma and says the product could eventually reach $3 billion-$5 billion in peak sales. The company also completed its Actio acquisition, adding the ABS-1230 epilepsy candidate.
• Neutral Sentiment: Jazz will present Phase 3 ACTION trial and other neuro-oncology data at the Society for Neuro-Oncology meeting later this month, creating a potential near-term catalyst but with clinical-outcome uncertainty. Jazz Pharmaceuticals neuro-oncology research
• Negative Sentiment: The quarterly loss compares with $8.13 in earnings per share a year earlier, while some commentary highlighted slowing growth and charges related to the Actio acquisition. These factors could limit enthusiasm despite the revenue beat.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $276.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, October 28th. Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Wall Street Zen lowered Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 3rd. Finally, Morgan Stanley upped their price target on shares of Jazz Pharmaceuticals from $314.00 to $319.00 and gave the company an “overweight” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $292.95.

Insider Activity

In other Jazz Pharmaceuticals news, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the transaction, the executive vice president directly owned 65,686 shares of the company’s stock, valued at $16,401,794.20. This trade represents a 53.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $236.40, for a total transaction of $472,800.00. Following the completion of the transaction, the chief executive officer directly owned 141,394 shares of the company’s stock, valued at approximately $33,425,541.60. The trade was a 1.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 94,121 shares of company stock valued at $23,337,922. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JAZZ. Bank of New York Mellon Corp lifted its holdings in shares of Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after purchasing an additional 517,514 shares during the last quarter. Tri Locum Partners LP bought a new stake in Jazz Pharmaceuticals in the first quarter worth $29,995,000. Bank of America Corp DE grew its stake in shares of Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after acquiring an additional 99,656 shares during the last quarter. Amundi grew its stake in shares of Jazz Pharmaceuticals by 2,445.3% in the first quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock worth $10,519,000 after acquiring an additional 53,454 shares during the last quarter. Finally, Rokos Capital Management LLP bought a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $9,833,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

The firm has a fifty day moving average price of $231.16 and a two-hundred day moving average price of $216.50. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $15.06 billion, a P/E ratio of 16.02, a P/E/G ratio of 0.41 and a beta of 0.38.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.